OMA Guidelines Bundle

Obesity Bariatric Surgery 2026

Obesity Medicine Association OMA GUIDELINES App Bundle brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1544295

Contents of this Issue

Navigation

Page 1 of 21

2 Bariatric Devices and Nonsurgical Procedures Key Points 1. Bariatric devices and nonsurgical procedures are often considered by patients seeking a less invasive and organ-sparing option for bariatric treatment. 2. Devices are used as a temporary measure to assist with weight loss before subsequent operations, such as joint repair or hernia repair. 3. Some patients may seek out these procedures for cosmetic reasons, such as losing weight before a wedding or a significant life event. 4. Bariatric devices necessitate comparable preoperative and postoperative evaluation and monitoring as standard bariatric surgery procedures. 5. Access can be limited due to factors such as surgeon expertise, institutional barriers, the volume of procedures, insurance coverage, and socioeconomic factors that affect access to care. 6. These devices are authorized for use exclusively in adults; they are not approved for use in children. Procedures and Devices Currently Available Endoscopic Sleeve Gastroplasty (ESG), or the OverStitch Device   ➤ Procedure: Endoscopic suturing of the stomach, creating a full- thickness plication of gastric tissue using permanent or absorbable sutures (see Endoscopic Sleeve Gastroplasty Procedure figure).   ➤ Effect: Shortens the length of the stomach.   ➤ Indication: Body mass index (BMI) 30–50 kg/m 2 .   ➤ Efficacy: 13% to 18% total body weight loss (TBWL) at one year and 12% to 16% at 5 years.   ➤ Comorbidities: Improvement of at least one weight-related chronic disease in 80% of individuals.   ➤ Safety: Risks include stitch failure, upper gastrointestinal bleeding, perigastric leak/infection, perforation, nausea, vomiting, abdominal pain, and heartburn. Major adverse events have an incidence of 2.2%.   ➤ Mortality: No deaths observed in published ESG literature.

Articles in this issue

Archives of this issue

view archives of OMA Guidelines Bundle - Obesity Bariatric Surgery 2026